Latest News

 Fremanezumab Safe and Effective for Prevention of Episodic Migraine in Children: Phase 3 Data Announced / image credit courtesy of Vall d'Hebron
Fremanezumab Safe and Effective for Prevention of Episodic Migraine in Children: Phase 3 Data Announced

December 5th 2024

The CGRP inhibitor fremanezumab reduced both monthly migraine and monthly headache days among children aged 6 to 17 years with a favorable safety profile.

Exercise of Any Level Cuts Mortality Risk in People with Dementia: Daily Dose / image credit: ©New Africa/AdobeStock
Exercise of Any Level Cuts Mortality Risk in People with Dementia: Daily Dose

December 5th 2024

New Review Highlights Need to Address Sleep Disturbances in Patients with Dementia / Image credit: ©netrun78/AdobeStock
New Review Highlights Need to Address Sleep Disturbances in Patients with Dementia

December 2nd 2024

Long-Term Study Provides Insights into Cognitive Aging: Daily Dose / image credit: ©New Africa/AdobeStock
Long-Term Study Provides Insights into Cognitive Aging: Daily Dose

November 28th 2024

Sex-Specific Dementia Risk in Older Adults with OSA: Daily Dose / image credit: ©New Africa/AdobeStock
Sex-Specific Dementia Risk in Older Adults with OSA: Daily Dose

November 26th 2024

Latest CME Events & Activities

5th Annual International Congress on the Future of Neurology®

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors

View More

Burst CME: Optimizing Therapy in Parkinson’s Disease

View More

Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders

View More

Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients

View More

Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders

View More

Little Voices, Big Challenges: Comprehensive Care for Pediatric Spinal Muscular Atrophy

January 9, 2025

Register Now!

Individualizing Treatment for Patients with Generalized Myasthenia Gravis

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care

View More

Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations

View More

BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders

View More

BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis

View More

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions

View More

Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Carolina Neuromuscular Summit

September 27, 2025

Register Now!

Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials

View More

More News

© 2024 MJH Life Sciences

All rights reserved.